Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session

675P - Assessing later-line treatment strategies and outcomes in EGFR oncogene-driven stage IV non-small cell lung cancer

Date

07 Dec 2024

Session

Poster Display session

Presenters

Meghana Maddula

Citation

Annals of Oncology (2024) 35 (suppl_4): S1632-S1678. 10.1016/annonc/annonc1698

Authors

M. Maddula1, V. Chin2, B. Brown3, J. Simes4, M. Boyer5

Author affiliations

  • 1 Medical Oncology, Crown Princess Mary Cancer Centre Westmead, 2145 - Westmead/AU
  • 2 Medical Oncology, Garvan Institute of Medical Research, 2010 - Darlinghurst/AU
  • 3 Research/enrich, NHMRC Clinical Trials Centre, 1450 - Camperdown/AU
  • 4 Nhmrc Clinical Trials Centre, University of Sydney, 2006 - Sydney/AU
  • 5 Medical Oncology, Chris O'Brien Lifehouse, 2050 - Camperdown/AU

Resources

This content is available to ESMO members and event participants.

Abstract 675P

Background

Metastatic non-small cell lung cancer (mNSCLC) has historically poor survival. Next-generation sequencing (NGS) has improved identification of oncogene driver mutations, present in 70%. While 1st line targeted therapies have improved outcomes, managing resistance remains a challenge. This study investigates 2nd line therapies in patients with Epidermal Growth Factor Receptor (EGFR) mutant mNSCLC.

Methods

The EnRICH study prospectively collected data on lung cancer patients across Australia. Patients with EGFR-driven mNSCLC were analysed. Endpoints included Progression-Free Survival 1 (PFS1) and 2 (PFS2), measured from first- and second-line treatments to disease progression respectively.

Results

Of the 2000 patients diagnosed with lung cancer between September 2016 - October 2021, 647 patients with NSCLC underwent molecular testing, revealing 21% with an EGFR mutation. 69 patients with EGFR mutations, who received first-line Tyrosine-Kinase Inhibitor (TKI) therapy and required subsequent therapy due to progressive disease underwent further analysis. In the first-line setting, 67% were treated with a first-generation TKI (Erlotinib: n=40, Gefitnib: n=7). Second-line, 49% received systemic therapy alone and 17% in combination with radiotherapy. A significant proportion (49%) were treated with second-line TKI, with the majority (93%) receiving the third-generation TKI Osimertinib. Overall median PFS1 was 8 months and PFS2 was 8 months. PFS2 was statistically superior in the TKI cohort compared with the chemotherapy/immunotherapy cohort (12 vs 5 months, P=0.005).

Conclusions

This study uses real-world data from the EnRICH database, representing the largest retrospective analysis of this cohort in Australia. It highlights the trend toward utilising second-line Osimertinib and suggests its potential superiority compared to other therapies. These results offer valuable insights into real-world management strategies and emphasises the need to refine them, particularly with the growing availability of NGS and next-generation TKIs, to enhance patient outcomes.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.